查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1831004

眼部过敏治疗市场

Eye Allergy Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

预计眼部过敏治疗市场将从 2024 年的 42.8 亿美元成长到 2031 年的 59.3 亿美元，2025 年至 2031 年的复合年增长率为 5.9%。

市场洞察与分析师观点：眼部过敏治疗包括非处方药和处方药，旨在缓解眼部发红、搔痒、流泪和肿胀等症状。常用产品包括抗组织胺眼药水、肥大细胞稳定剂和合併疗法。眼睛过敏的主要类型包括季节性或常年性过敏性结膜炎、春季角结膜炎、异位性角结膜炎和接触性过敏性结膜炎。全球眼部过敏发生率的上升，以及非处方药的普及，推动了眼部过敏治疗市场的成长。

成长驱动因素：眼部过敏，又称为过敏性结膜炎，是由花粉、灰尘、宠物皮屑和霉菌等过敏原引发的。空气污染加剧导致眼部过敏病例增加。此外，生活型态的改变、饮食习惯的改变、接触过敏原的增加、萤幕使用时间的增加导致眼部疲劳，以及对眼部不适的敏感度增强，都导致全球人口眼部过敏反应显着增加。

2020年发表的一项名为《过敏性结膜炎的当代视角》的研究表明，过敏性眼疾在北美普遍存在，影响着近40%的人口，而且这一数字还在持续上升。大约一半的美国眼部过敏症状患者寻求药物治疗，但只有一小部分人使用处方药，凸显了新疗法发展的潜力。

眼部过敏治疗产品涵盖用于控制和缓解眼部过敏相关症状的产品。这些产品包括非处方药和处方药，用于缓解眼部发红、搔痒、流泪和肿胀等症状。常见产品包括抗组织胺眼药水、肥大细胞稳定剂和非类固醇类抗发炎药。眼部过敏患者数量的不断增长推动了对治疗方案的需求，从而推动了市场的成长。

眼部过敏治疗市场的当前趋势包括联合疗法的开发，预计未来将进一步促进市场成长。

战略洞察

报告细分和范围：透过研究治疗类型、适应症、配销通路和地理等不同细分市场，对眼部过敏治疗市场进行了分析。治疗领域包括药物、过敏针剂和眼药水。适应症领域分为季节性和常年性过敏性结膜炎、春季角结膜炎、特异性角结膜炎、接触性过敏性结膜炎和巨乳头状结膜炎。分销管道分为医院药局、线上药局和药局。

眼部过敏治疗市场报告的范围涵盖北美（美国、加拿大和墨西哥）、欧洲（法国、德国、英国、西班牙、义大利和欧洲其他地区）、亚太地区（中国、日本、印度、韩国、澳洲和亚太其他地区）、中东和非洲（沙乌地阿拉伯、阿联酋、南非和中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲其他地区）。

細項分析：眼部过敏治疗市场依治疗方法分为药物、过敏注射剂和眼药水。眼药水细分市场在2022年占据了相当大的市场份额，预计在2022-2030年期间的复合年增长率最高。

根据适应症，市场分为季节性和常年性过敏性结膜炎、春季角结膜炎、特异性角结膜炎、接触性过敏性结膜炎和巨乳头状结膜炎。季节性和常年性过敏性结膜炎在2022年占据了相当大的市场份额，预计在2022年至2030年期间将实现最高的复合年增长率。

就分销管道而言，市场细分为医院药房、线上药局和药局。医院药局在2022年占据了相当大的市场份额，而线上药局预计将在2022-2030年期间实现最高的复合年增长率。

区域分析：眼部过敏治疗市场报告主要按地理细分为北美、欧洲、亚太地区、南美和中美以及中东和非洲。 2022 年，北美占据了相当大的市场份额，其中美国占据主导地位。北美的成长归功于先进的医疗基础设施、主要市场参与者的强大影响力、眼睛过敏和干眼症患者的增多以及创新药物的推出。根据浸信会健康中心的数据，近 5,000 万美国人患有某种形式的季节性过敏，约 30% 的成人和 40% 的儿童会出现影响眼睛、眼睑和泪管的过敏反应。

干眼症会导致眼部过敏，进而引发干眼症。干眼症在美国是一种常见但常被误诊的疾病。 2020年发布的美国国家健康与保健调查数据显示，6.8%的美国成年人口被诊断为干眼症。 2019年发表的一篇题为《墨西哥干眼症患者眼表损伤的危险因子：一项基于人群的研究》的文章指出，近58%的墨西哥干眼症患者主诉干眼症。

製药公司正在提升专业治疗药物（例如抗过敏眼药水）的可及性，以扩大其在该地区市场的覆盖范围。自2022年3月起，艾尔建的LASTACAFT（0.25%阿卡他定滴眼液）已针对美国眼部过敏患者非处方笺销售。随着FDA近期批准其从处方药转为非处方药，LASTACAFT的原始专利处方药配方现已可在网上和销售非处方眼药水的零售店购买。这些因素正在推动该地区眼部过敏治疗市场的成长。

眼部过敏治疗市场报告范围

产业发展与未来机会：全球眼部过敏治疗市场参与者采取的几项措施包括：

2020年9月，雷迪博士实验室在美国市场推出了一款非处方眼部过敏眼药水－盐酸奥洛他定滴眼液，用于暂时缓解因花粉、草屑、动物毛髮和皮屑引起的眼部搔痒。 2020年2月，爱尔康公司获得美国食品药物管理局（FDA）批准，允许Pataday公司每日一次和每日两次的眼部过敏瘙痒缓解配方在美国非处方销售。 Pataday品牌采用领先的医生处方眼部过敏瘙痒缓解成分，并包含首款无需处方即可获得的每日一次的过敏瘙痒缓解滴眼液。

竞争格局和主要公司：眼部过敏治疗市场的预测可以帮助利害关係人规划其成长策略。市场的主要参与者包括博士伦、爱尔康、艾伯维、强生、Akorn Inc.、Nicox、参天製药有限公司、梯瓦製药工业有限公司、诺华公司和太阳製药工业有限公司。这些公司专注于推出创新产品、增强现有产品并拓展地理范围，以满足全球日益增长的消费者需求。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：眼部过敏治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：眼部过敏治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：眼部过敏治疗市场－全球市场分析

  • 眼部过敏治疗－全球市场概览
  • 眼部过敏治疗－全球市场及2030年预测

第七章：眼部过敏治疗市场-收入分析-依治疗类型，2020-2030

  • 概述
  • 药物
  • 过敏针
  • 眼药水

第 8 章：眼部过敏治疗市场 - 收入分析 - 按适应症，2020-2030 年

  • 概述
  • 季节性和常年性过敏性结膜炎
  • 春季角结膜炎
  • 特应性角结膜炎
  • 接触性过敏性结膜炎
  • 巨乳头性结膜炎

第九章：眼部过敏治疗市场-收入分析-按配销通路，2020-2030年

  • 概述
  • 医院药房
  • 网路药局
  • 药局

第 10 章：眼部过敏治疗市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：眼部过敏治疗市场 - 主要公司简介

  • Bausch and Lomb
  • Alcon
  • Johnson and Johnson Services Inc
  • AbbVie
  • Akorn Inc.
  • Nicox
  • Santen Pharmaceutical Co. Ltd
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

第 14 章：附录

简介目录
Product Code: TIPRE00007418

The eye allergy treatment market is anticipated to grow from US$ 4.28 billion in 2024 to US$ 5.93 billion by 2031, reflecting a CAGR of 5.9% from 2025 to 2031.

Market Insights and Analyst Perspective:Eye allergy treatments encompass both over-the-counter and prescription medications aimed at relieving symptoms such as redness, itching, tearing, and swelling of the eyes. Commonly utilized products include antihistamine eye drops, mast cell stabilizers, and combination therapies. The main types of eye allergies include seasonal or perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and contact allergic conjunctivitis. The rising incidence of eye allergies globally, along with the accessibility of over-the-counter treatments, supports the growth of the eye allergy treatment market.

Factors Driving Growth:Eye allergies, or allergic conjunctivitis, are triggered by allergens such as pollen, dust, pet dander, and mold. Increasing air pollution levels have led to a rise in eye allergy cases. Additionally, lifestyle changes, dietary habits, greater exposure to allergens, increased screen time causing eye strain, and heightened sensitivity to eye discomfort have all contributed to a significant increase in allergic reactions affecting the eyes among the global population.

A study titled "A Contemporary Look at Allergic Conjunctivitis," published in 2020, indicates that allergic eye disease is prevalent in North America, affecting nearly 40% of the population, a figure that continues to rise. Approximately half of the US population experiencing ocular allergy symptoms seek medication for relief, yet only a small percentage utilize prescription treatments, highlighting the potential for new treatment developments.

Eye allergy treatments consist of products designed to manage and alleviate symptoms associated with eye allergies. These include over-the-counter medications and prescription drugs that address symptoms like redness, itching, tearing, and swelling. Common products include antihistamine eye drops, mast cell stabilizers, and nonsteroidal anti-inflammatory drugs. The increasing number of individuals suffering from eye allergies drives the demand for treatment options, thereby propelling market growth.

Current trends in the eye allergy treatment market include the development of combination therapies, which are expected to further enhance market growth in the future.

Strategic Insights

Report Segmentation and Scope:The analysis of the eye allergy treatment market has been conducted by examining various segments: treatment type, indication, distribution channel, and geography. The treatment segment includes medication, allergy shots, and eye drops. The indication segment is divided into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis. Distribution channels are categorized into hospital pharmacies, online pharmacies, and drug stores.

The scope of the eye allergy treatment market report encompasses North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The eye allergy treatment market is categorized by treatment into medication, allergy shots, and eye drops. The eye drops segment accounted for a significant market share in 2022 and is projected to exhibit the highest CAGR during 2022-2030.

By indication, the market is divided into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis. The seasonal and perennial allergic conjunctivitis segment held a substantial market share in 2022 and is expected to register the highest CAGR from 2022 to 2030.

In terms of distribution channels, the market is segmented into hospital pharmacies, online pharmacies, and drug stores. The hospital pharmacies segment held a significant market share in 2022, while the online pharmacy segment is anticipated to achieve the highest CAGR during 2022-2030.

Regional Analysis:The eye allergy treatment market report is primarily segmented by geography into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America held a significant market share in 2022, with the US leading the region. The growth in North America is attributed to the presence of advanced healthcare infrastructure, a strong presence of key market players, an increasing number of eye allergies and dry eye diseases, and the introduction of innovative medications. According to Baptist Health, nearly 50 million Americans suffer from some form of seasonal allergy, with about 30% of adults and 40% of children experiencing allergic reactions affecting their eyes, eyelids, and tear ducts.

Dry eye conditions can lead to eye allergies, which may subsequently result in dry eye disease. Dry eye disease is a common yet often underdiagnosed condition in the US. Data from the National Health and Wellness Survey published in 2020 indicated that 6.8% of the adult population in the US was diagnosed with dry eye. An article titled 'Risk factors for ocular surface damage in Mexican patients with dry eye disease: a population-based study,' published in 2019, reported that nearly 58% of individuals complained of dry eyes.

Pharmaceutical companies are enhancing access to specialized treatments, such as allergy-relieving eye drops, to broaden their market reach in the region. As of March 2022, Allergan's LASTACAFT (alcaftadine ophthalmic solution 0.25%) became available to Americans with ocular allergies without a prescription. Following the recent FDA approval for the switch from prescription to over-the-counter, the original patented prescription-strength formulation of LASTACAFT can now be found online and in retail stores where OTC eye drops are sold. These factors are driving the growth of the eye allergy treatment market in the region.

Eye Allergy Treatment Market Report Scope

Industry Developments and Future Opportunities:Several initiatives by market players in the global eye allergy treatment market include:

In September 2020, Dr Reddy's Laboratories launched an over-the-counter eye allergy drop, Olopatadine Hydrochloride Ophthalmic Solution, in the US market, indicated for temporary relief of itchy eyes due to pollen, grass, animal hair, and dander.In February 2020, Alcon received FDA approval for Pataday's once-daily and twice-daily relief formulations for over-the-counter sale in the US. The Pataday brand features the leading doctor-prescribed ingredient for eye allergy itch relief and includes the first once-daily allergy itch relief drop available without a prescription.

Competitive Landscape and Key Companies:The forecast for the eye allergy treatment market can assist stakeholders in planning their growth strategies. Key players in the market include Bausch + Lomb, Alcon, AbbVie, Johnson & Johnson, Akorn Inc., Nicox, Santen Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, Novartis AG, and Sun Pharmaceutical Industries Ltd. These companies are focused on launching innovative products, enhancing existing offerings, and expanding geographically to meet the increasing consumer demand globally.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Eye Allergy Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Eye Allergy Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Eye Allergy Treatment Market - Global Market Analysis

  • 6.1 Eye Allergy Treatment - Global Market Overview
  • 6.2 Eye Allergy Treatment - Global Market and Forecast to 2030

7. Eye Allergy Treatment Market - Revenue Analysis (USD Million) - By Treatment, 2020-2030

  • 7.1 Overview
  • 7.2 Medication
  • 7.3 Allergy Shots
  • 7.4 Eye Drops

8. Eye Allergy Treatment Market - Revenue Analysis (USD Million) - By Indication, 2020-2030

  • 8.1 Overview
  • 8.2 Seasonal and Perennial Allergic Conjunctivitis
  • 8.3 Vernal keratoconjunctivitis
  • 8.4 Atopic keratoconjunctivitis
  • 8.5 Contact Allergic Conjunctivitis
  • 8.6 Giant Papillary Conjunctivitis

9. Eye Allergy Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Online Pharmacy
  • 9.4 Drug Stores

10. Eye Allergy Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Eye Allergy Treatment Market Overview
    • 10.1.2 North America Eye Allergy Treatment Market Revenue and Forecasts to 2030
    • 10.1.3 North America Eye Allergy Treatment Market Revenue and Forecasts and Analysis - By Treatment
    • 10.1.4 North America Eye Allergy Treatment Market Revenue and Forecasts and Analysis - By Indication
    • 10.1.5 North America Eye Allergy Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Eye Allergy Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Eye Allergy Treatment Market
        • 10.1.6.1.1 United States Eye Allergy Treatment Market, by Treatment
        • 10.1.6.1.2 United States Eye Allergy Treatment Market, by Indication
        • 10.1.6.1.3 United States Eye Allergy Treatment Market, by Distribution Channel
      • 10.1.6.2 Canada Eye Allergy Treatment Market
        • 10.1.6.2.1 Canada Eye Allergy Treatment Market, by Treatment
        • 10.1.6.2.2 Canada Eye Allergy Treatment Market, by Indication
        • 10.1.6.2.3 Canada Eye Allergy Treatment Market, by Distribution Channel
      • 10.1.6.3 Mexico Eye Allergy Treatment Market
        • 10.1.6.3.1 Mexico Eye Allergy Treatment Market, by Treatment
        • 10.1.6.3.2 Mexico Eye Allergy Treatment Market, by Indication
        • 10.1.6.3.3 Mexico Eye Allergy Treatment Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Eye Allergy Treatment Market - Key Company Profiles

  • 13.1 Bausch and Lomb
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Alcon
  • 13.3 Johnson and Johnson Services Inc
  • 13.4 AbbVie
  • 13.5 Akorn Inc.
  • 13.6 Nicox
  • 13.7 Santen Pharmaceutical Co. Ltd
  • 13.8 Teva Pharmaceutical Industries Ltd
  • 13.9 Novartis AG
  • 13.10 Sun Pharmaceutical Industries Ltd.

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud